Investors sought for Sapvax cancer vaccine spin-out 6 Jul 2015
Related articles
- NZ consumers grow more upbeat, may resume spending Business
- Knowles quits as CEO of KiwiBank Business
- NZ migration bolstered by British invasion Migration
- NZ manufacturing activity reaches highest since 04 Business
- NZ dollar hits 22-month high vs euro Business
- Budget provides $321m for RS&T activities News
- OceanaGold finds new gold deposits at Fraser mine Business
- Transpower gets go-ahead for $170m SI upgrade Business
- NZ home sales creep up in March, still subdued Property
- NZ economy expands at fastest pace in two years Business
Investors sought for Auckland University's Sapvax cancer vaccine spin-out
By Fiona Rotherham
July 6
(BusinessDesk) - Investors are being sought for US$8
million of funding to commercialise an anti-cancer vaccine
using immunotherapy technology developed by a team led by
Maurice Wilkins Centre director Rod Dunbar and Margaret
Brimble, director of Auckland University’s medicinal
chemistry programme.
UniServices, the University of Auckland’s commercial arm, is setting up the spin-out company, Sapvax, to commercialise the patented vaccines.
The research has run in parallel with that
underway at the Malaghan Institute and Victoria
University’s Ferrier Research Institute, which has set up
a company called Avalia Immunotherapies to commercialise a
synthetic vaccine technology which also uses a patient’s
own immune system to recognise and attack cancer
cells.
Unlike traditional vaccines, cancer vaccines
are administered after the disease has developed and can be
used alongside traditional cancer treatments such as
radiation and chemotherapy.
Dunbar said Sapvax vaccines are ready, pending regulatory approval, to move to clinical trials.
“New Zealand has a lot of capability in this field,” with a pipeline of products targeting cancer immunotherapy, he said.
Cancer cells can initially seem normal to the immune system, tricking the body into thinking nothing is wrong. The synthetic peptide vaccines alert the immune system, and trigger immune cells called T cells to search for and kill cancer tumours.
Molecules within the vaccines alert the immune system there is danger present. The rest of the vaccines are made up of synthetic molecules that mimic ones found in cancer cells. Together, the combined vaccines tell the immune system to seek and destroy any calls carrying the same molecules as the vaccines, which were previously unrecognised as a threat.
Cancer vaccines alone have shown to be effective in only a small number of cancer patients, but their real value is in being used alongside new immunotherapy drugs, called checkpoint blockers, which re-activate immune cells that have been switched off by the cancer cells.
While some patients have responded well to these drugs, many others haven’t. One reason they may not work is that the patients’ immune cells have never recognised the tumour and on those patients, Sapvax vaccines could combine with checkpoint blockers to cause a durable remission from cancer.
“It’s like an off button. With vaccines
alone the tumours can turn on the off button and the T cells
stop working. The anti-PD-1 drugs put a plastic barrier over
the red button and the tumour can’t put it back on and the
vaccines can work better,” Dunbar said.
“Cancer vaccines are a hot area of development to go with these drugs,” said Adam Podmore, UniServices commercialisation manager. Cancer immunotherapy is estimated to become a US$35 billion per year market within the next decade and “these vaccines” are part of that, Podmore said.
He said Sapvax targets a different process of immune activation from the Avalia vaccine, using a unique chemistry that involves a single step to “clip on” the immune activator.
Connecting the cancer molecule and the danger signal in a single reaction makes them simple and flexible to manufacture. The vaccines can be changed easily when a different type of cancer is being targeted.
Podmore said US$2.5 million of the equity investment will be spent on an 18-month clinical trial in Auckland involving around 20 cancer patients on the first patented vaccine product, SV-283, which targets cancers including melanoma, sarcoma, ovarian, and non-small cell lung cancer.
He said Sapvax’s platform technology includes different vaccines for various types of cancers and eventually other diseases. A second product, SV-638, is also well down the development pipeline and targets Epstein Barr Virus-positive tumours, such as lymphoma and nasopharyngeal cancer (a rare type of head and neck cancer).
“We’re looking for someone with money to invest and with the ability to manage and put management teams in place to commercialise this technology,” Podmore said. An alternative is licensing the technology to an existing company.
Auckland University has a GMP peptide facility, which has had previous Medsafe approval to manufacture medicines, that can make the peptides used in the vaccines.
Brimble said Sapvax will be the first spin-out company she’s been involved in. “It’s one of the things I’ve wanted to do,” she said.
(BusinessDesk)
News
Hilary Timmins' Award-Winning UK Documentary Series To Inspire NZ Students
29 Jun 2020 Education
Dream Catchers, produced and directed by Hilary Timmins, celebrates the success stories of more than thirty inspirational New... more
New Zealand reaffirms support for Flight MH17 judicial process
7 Mar 2020 News
Ahead of the start of the criminal trial in the Netherlands on 9 March, Foreign Minister Winston Peters has reaffirmed the need to... more
Business
NZ Government's Economic package to fight COVID-19
17 Mar 2020 Business News
The Coalition Government has launched the most significant peace-time economic plan in modern New Zealand history to cushion the... more
NZ Government announces aviation relief package
19 Mar 2020 Business News
Transport Minister Phil Twyford today outlined the first tranche of the $600 million aviation sector relief package announced earlier... more
Living
Diversity was Key at New Zealand Trade Tasting in London
6 Jun 2022 Food & Wine
New Zealand Winegrowers Annual Trade Tasting was recently held in London, on Wednesday 4 May, in Lindley Hall.
It was the first... more
Kiwi author stuns Behind the Butterfly Gate
12 Jan 2022 Arts
Hidden behind the Butterfly Gate is where the secret has been kept for 76 years...
New Zealand writer Merryn Corcoran’s... more
Property
Fairer rules for tenants and landlords
17 Nov 2019 Property
17 NOVEMBER 2019
The Government has delivered on its promise to the over one million New Zealanders who now rent to make it fairer... more
New Zealand Government will not implement a Capital Gains Tax
17 Apr 2019 Property
The Coalition Government will not proceed with the Tax Working Group’s recommendation for a capital gains tax, Jacinda Ardern... more
Migration
Boosting border security with electronic travel authority – now over 500,000 issued
19 Nov 2019 Migration
19 NOVEMBER 2019
We’ve improved border security with the NZeTA, New Zealand Electronic Travel Authority, which helps us to... more
Christchurch reinstated as refugee settlement location
18 Aug 2018 Migration
18 AUGUST 2018
HON IAIN LEES-GALLOWAY
The announcement that Christchurch can once again be a settlement location for refugees... more
Travel
Gallipoli Anzac Day services cancelled
19 Mar 2020 Travel & Tourism
The New Zealand and Australian Governments have announced this year’s joint Anzac Day services at Gallipoli will be cancelled... more
New Zealanders advised not to travel overseas
19 Mar 2020 Travel & Tourism
New Zealanders advised not to travel overseas
more
Sport
The Skipper's Diary: Sir Richard Hadlee honouring his father and NZ's Forty-Niners
27 Oct 2019 Cricket
NZNewsUK London Editor Charlotte Everett spoke to Sir Richard Hadlee about why he’s chosen to publish his father’s... more
PREVIEW: All Blacks v England semi-final
26 Oct 2019 Rugby
The two most convincing quarterfinals winners are set to square off in a semifinal showdown for the ages when the All Blacks meet old... more
Columns
Gordon Campbell on the Gareth Morgan crusade
11 Nov 2016 Opinion
Gordon Campbell on the Gareth Morgan crusade
First published on Werewolf
The ghastly likes of Marine Le Pen in France and Geert ... more
Gordon Campbell on the US election outcome
10 Nov 2016 Opinion
Column - Gordon Campbell
Gordon Campbell on the US election outcome
Well um.. on the bright side, there (probably)... more
Kiwi Success
Congratulations to Loder Cup winner
26 Sep 2018 People
25 SEPTEMBER 2018
The Loder Cup, one of New Zealand’s oldest conservation awards, has been awarded to Robert McGowan for 2018... more
Appointments to New Zealand National Commission for UNESCO
16 Aug 2018 Appointments
16 AUGUST 2018Appointments to New Zealand National Commission for UNESCO
HON JENNY SALESA
Associate Education Minister Jenny Salesa is... more
Recruitment
Historic pay equity settlement for education support workers
14 Aug 2018 Recruitment
14 AUGUST 2018Historic pay equity settlement for education support workers
RT HON JACINDA ARDERN
HON CHRIS HIPKINS
Prime Minister
The... more
Historic pay equity settlement for education support workers
22 Aug 2018 Recruitment
14 AUGUST 2018Historic pay equity settlement for education support workers
RT HON JACINDA ARDERN
HON CHRIS HIPKINS
Prime Minister
The... more